8-K Announcements
6Material company update
Feb 23, 2026·SEC
Material company update
Dec 31, 2025·SEC
Material company update
Nov 18, 2025·SEC
Avenue Therapeutics, Inc.(ATXI)Earnings, Financials & Key Ratios
ATXI•NASDAQ
$0.33
Price updated Jul 6, 2026
AboutAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.Show more
- Revenue$1M
- EBITDA-$3M+71.9%
- Net Income-$3M+75.0%
- EPS (Diluted)-0.93-3.3%
- Gross Margin100%
- EBITDA Margin-234.05%
- Operating Margin-234.05%
- Net Margin-207.19%
- ROE-157.75%+83.0%
ATXI Price & Volume
Avenue Therapeutics, Inc. (ATXI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Regulatory Hurdles Threaten Capital Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary Regulatory Approval Failure
Key Thesis Takeaways
- Avenue Therapeutics remains a high-risk, pre-commercial entity whose valuation is entirely dependent on overcoming significant FDA regulatory barriers for its lead analgesic candidate.
- The company lacks a sustainable, recurring revenue model, with historical top-line performance limited to a single $1.4M milestone payment in 2025Q2.
- Investors face substantial dilution risk as the firm continues to burn through its remaining $2.4M cash balance to fund ongoing R&D and SG&A expenses.
Verdict Logic
the company's reliance on binary regulatory outcomes and a dwindling cash reserve of only $2.4M as of 2026Q1 present an unacceptable risk profile for institutional capital.
ATXI Growth Metrics
Avenue Therapeutics, Inc. (ATXI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM87.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM88.04%
Return on Capital
10 Years-395.43%
5 Years-437.45%
3 Years-606.36%
Last Year-178.2%
ATXI Recent Earnings
Avenue Therapeutics, Inc. (ATXI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (50%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.21+99.6%
$56.25
Rev
—
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.22+99.6%
$56.25
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.21
—
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.11
—
Rev
$1M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.21vs $56.25+99.6% | — |
| Q2 2026 | Mar 30, 2026 | $0.22vs $56.25+99.6% | — |
| Q4 2025 | Nov 13, 2025 | $0.21 | — |
| Q3 2025 | Aug 14, 2025 | $0.11 | $1M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Avenue Therapeutics, Inc. (ATXI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.33 | $1.09M | -0.35 | — | -207.19% | -157.75% | — | |
| $25.59 | $1.01B | 159.94 | 3.63% | 1.27% | 1.31% | — | |
| $37.47 | $1.22B | 21.66 | 23.62% | 9.41% | 26.74% | — | |
| $4.27 | $1.32B | 213.50 | 22.23% | -6.63% | — | — | |
| $3.14 | $345.48K | -0.33 | — | -227.72% | -25.53% | — | |
| $73.15 | $1.43B | -7.52 | -43.89% | -284.18% | -87% | — |
Compare ATXI vs Peers
Avenue Therapeutics, Inc. (ATXI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATXI SEC Filings & Documents
Avenue Therapeutics, Inc. (ATXI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ATXI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ATXI Frequently Asked Questions
Avenue Therapeutics, Inc. (ATXI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Avenue Therapeutics, Inc.'s revenue?
Avenue Therapeutics, Inc. (ATXI) reported $1.4M in revenue for fiscal year 2025.
Is ATXI profitable?
Avenue Therapeutics, Inc. (ATXI) reported a net loss of $1.8M for fiscal year 2025.
Dividend & Returns
What is ATXI's return on equity?
Avenue Therapeutics, Inc. (ATXI) has a return on equity (ROE) of -157.8%. Negative ROE indicates the company is unprofitable.
What is Avenue Therapeutics, Inc.'s free cash flow?
Avenue Therapeutics, Inc. (ATXI) had negative free cash flow of $1.1M in fiscal year 2025, likely due to heavy capital investments.